NEOS (MC $95 M) $60 M Cash 1 Drug approved 2 more under review by FDA targeting Billion Dollar Markets . Very attractive and unknown FDA play with HUGE upside Potential i see thefair value around $20 per share .GL NEOS Therapeutics (NEOS) Market Cap: $95 M Cash: $60 M Price $6 Shares Out: 16.06 M Presentation http://investors.neostx.com/phoenix.zhtml?c=254075&p=irol-presentations •Adzenys XR-ODT launched May, 2016 •Robust prescription growth since launch •22,797 total TRx through December 2, 2016 •Pipeline includes two late-stage product candidates for the treatment of ADHD •Amphetamine XR-Oral Suspension —NDA Submitted Nov 15, 2016 •Cotempla (methylphenidate) XR-ODT —NDA resubmitted Dec 20, 2016